市場調査レポート
商品コード
1462256
CVN-424の市場規模、予測、新薬の考察(2032年)CVN-424 Market Size, Forecast, and Emerging Insight - 2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
CVN-424の市場規模、予測、新薬の考察(2032年) |
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2~10営業日
|
CVN-424は、パーキンソン病治療薬として開発中の新規ターゲット(GPR6)に作用するファーストインクラスの経口非ドパミン作動性化合物です。パーキンソン病に関連するD2受容体依存的で間接的な経路を選択的に標的とし、パーキンソン病の現在の標準治療であるレボドパと脳深部刺激療法の効果を、副作用なしに得ることを目的としています。CVN424は、パーキンソン病患者を対象としたフェーズII試験において、臨床的に意義のある有意な有効性を示しました。さらに企業は、レボドパによる治療を受けていない新たに診断されたパーキンソン病患者を対象に、単剤療法としてのCVN424を評価するフェーズII概念実証試験を2023年第2四半期に開始する予定であり、また、補助療法としての承認取得を目指し、本薬をさらに評価するフェーズII/III臨床試験を開始する予定です。
当レポートでは、主要7市場(米国・ドイツ・フランス・イタリア・スペイン・英国・日本)におけるパーキンソン病向けCVN-424について調査分析し、作用機序、用法と用量、研究開発活動についての考察、収益の予測などを提供しています。
"CVN-424 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about CVN-424 for Parkinson's disease in the seven major markets. A detailed picture of the CVN-424 for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the CVN-424 for Parkinson's Disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the CVN-424 market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.
CVN-424, Cerevance's lead therapeutic, is a first-in-class, oral, non-dopaminergic compound acting on a novel target (GPR6) in development for the treatment of Parkinson's disease. It selectively targets the D2 receptor-dependent, indirect pathway associated with Parkinson's disease and is intended to generate the positive effects of levodopa and deep brain stimulation, the current standard of care for Parkinson's disease, without the adverse effects. CVN424 demonstrated significant and clinically meaningful efficacy in a Phase II study in patients with Parkinson's disease. Additionally, the company planned to initiate a Phase II proof of concept study assessing CVN424 as a monotherapy treatment in patients with newly diagnosed Parkinson's disease not yet treated with levodopa in Q2 2023 and Phase II/III clinical study to further assess the drug with intentions of seeking regulatory approval as an adjunctive therapy.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
CVN-424 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of CVN-424 for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.
The report provides the clinical trials information of CVN-424 for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.